tiprankstipranks
9 Meters Biopharma trial design increases odds of success, says Brookline
The Fly

9 Meters Biopharma trial design increases odds of success, says Brookline

After 9 Meters Biopharma announced the design of its Phase 3 clinical trial of vurolenatide for adults with short bowel syndrome, Brookline analyst Kumaraguru Raja said the trial design increases the odds of success given that hitting either of its endpoints can support an NDA filing. Raja reiterates a Buy rating and $74 price target on 9 Meters shares.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on NMTR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles